Summit Therapeutics Inc. (SMMT) Faces Volatile 2025 as Ivonescimab Gains Approval in China

In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Summit Therapeutics Inc. stands amongst them.

Summit Therapeutics Inc. (NASDAQ:SMMT), a biopharmaceutical company focused on non-small cell lung cancer (NSCLC), has made significant strides with its lead investigational drug, ivonescimab. The HARMONi Phase III trial for EGFR-mutated NSCLC patients demonstrated a statistically significant improvement in progression-free survival when ivonescimab was combined with platinum-based chemotherapy versus placebo. While overall survival trends were positive, they did not reach statistical significance.

Summit Therapeutics Inc. (NASDAQ:SMMT) recently received approval in China for ivonescimab as a first-line treatment for PD-L1-positive advanced NSCLC, reflecting geographic expansion. Patient enrollment is ongoing in global Phase III trials, including the newly initiated U.S. cohorts, highlighting continued momentum in clinical development.

Summit Therapeutics Inc. (SMMT) Faces Volatile 2025 as Ivonescimab Gains Approval in China

Despite these advances, the business’s stock has faced volatility in 2025. Investor concerns have arisen from mixed trial outcomes in North America and Europe compared to stronger results in China, raising questions about broader commercial potential. Additionally, Summit Therapeutics Inc. (NASDAQ:SMMT) is navigating legal scrutiny from a securities fraud lawsuit tied to the Pinnacle Study.

While we acknowledge the risk and potential of SMMT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SMMT and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.